Xilio Therapeutics, Inc. Financials
Xilio Therapeutics, Inc. (XLO) reported $43.8M in revenue for fiscal year 2025, up 589.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing and a sharp drop in cash burn became the dominant mechanic behind Xilio’s FY2025 balance-sheet reset.
By FY2025, operating cash burn had fallen to-$5.0M from roughly-$69M two years earlier, a much bigger improvement than the loss line alone implies. Cash still rose to$137.5M because financing inflows added$87.8M ; with free cash flow nearly matching operating cash flow, this is an operating-spend business whose cash needs come mainly from research and overhead rather than capital equipment.
R&D spending remained above revenue in FY2025, at
The balance sheet is liquid in the short term: current assets covered current liabilities by 2.6x. But it is also thinly capitalized, with equity of only
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Xilio Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Xilio Therapeutics, Inc. has an operating margin of -95.9%, meaning the company loses $96 on every $100 of revenue. This results in a profitability score of 15/100. This is up from -955.0% the prior year.
Xilio Therapeutics, Inc.'s revenue surged 589.9% year-over-year to $43.8M, reflecting rapid business expansion. This strong growth earns a score of 99/100.
Xilio Therapeutics, Inc. has elevated debt relative to equity (D/E of 3.39), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 18/100, reflecting increased financial risk.
With a current ratio of 2.58, Xilio Therapeutics, Inc. holds $2.58 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.
Xilio Therapeutics, Inc.'s operations used $5.0M of cash, and capex of $518K added to the outflow, for a free cash flow shortfall of $5.5M. This results in a cash flow score of 6/100.
Xilio Therapeutics, Inc. posts a -99.3% return on equity (ROE), meaning it loses $99 for every $100 of shareholders' equity. This results in a returns score of 20/100. This is up from -330.9% the prior year.
Xilio Therapeutics, Inc. scores -3.41, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($60.7M) relative to total liabilities ($119.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Xilio Therapeutics, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Xilio Therapeutics, Inc. reported a net loss of $35.0M while operations used $5.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Xilio Therapeutics, Inc. generated $43.8M in revenue in fiscal year 2025. This represents an increase of 589.9% from the prior year.
Xilio Therapeutics, Inc.'s EBITDA was -$40.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.4% from the prior year.
Xilio Therapeutics, Inc. reported -$35.0M in net income in fiscal year 2025. This represents an increase of 39.8% from the prior year.
Xilio Therapeutics, Inc. earned -$4.19 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Xilio Therapeutics, Inc. recorded an outflow of $5.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 70.1% from the prior year.
Xilio Therapeutics, Inc. held $137.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Xilio Therapeutics, Inc.'s operating margin was -95.9% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Xilio Therapeutics, Inc.'s net profit margin was -80.0% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Xilio Therapeutics, Inc.'s ROE was -99.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 231.6 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Xilio Therapeutics, Inc. invested $56.0M in research and development in fiscal year 2025. This represents an increase of 36.0% from the prior year.
Xilio Therapeutics, Inc. invested $518K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1338.9% from the prior year.
Not reported for fiscal year 2025.
XLO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | $64.1M | $43.8M+589.9% | $6.3M | N/A | N/A | N/A | N/A |
| R&D Expenses | $66.8M | $56.0M+36.0% | $41.2M-21.0% | $52.1M-11.9% | $59.2M+15.7% | $51.2M+16.6% | $43.9M |
| SG&A Expenses | $28.6M | $29.7M+19.9% | $24.8M-8.2% | $27.0M-9.9% | $29.9M+25.5% | $23.9M+123.9% | $10.7M |
| Operating Income | -$31.4M | -$42.0M+30.7% | -$60.6M+23.4% | -$79.1M+11.2% | -$89.1M-18.8% | -$75.0M-37.5% | -$54.6M |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$21.8M | -$35.0M+39.8% | -$58.2M+23.8% | -$76.4M+13.4% | -$88.2M-16.4% | -$75.8M-37.3% | -$55.2M |
| EPS (Diluted) | — | -$4.19 | -$15.24 | -$2.78+13.7% | -$3.22 | -$13.52 | -$105.42 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
XLO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $154.7M+117.6% | $71.1M+16.7% | $60.9M-56.2% | $139.2M-36.2% | $218.1M+500.4% | $36.3M |
| Current Assets | $145.0M+140.8% | $60.2M+25.2% | $48.1M-61.3% | $124.5M-38.5% | $202.5M+883.6% | $20.6M |
| Cash & Equivalents | $137.5M+148.7% | $55.3M+23.7% | $44.7M-62.9% | $120.4M-39.2% | $198.1M+929.5% | $19.2M |
| Total Liabilities | $119.4M+123.3% | $53.5M+121.9% | $24.1M-28.1% | $33.5M+2.7% | $32.6M-72.7% | $119.6M |
| Current Liabilities | $56.3M+106.4% | $27.3M+70.8% | $16.0M-24.4% | $21.1M+65.3% | $12.8M-42.3% | $22.2M |
| Total Equity | $35.3M+100.4% | $17.6M-52.2% | $36.8M-65.1% | $105.6M-43.0% | $185.4M+322.6% | -$83.3M |
| Retained Earnings | -$418.8M-9.1% | -$383.8M-17.9% | -$325.5M-30.7% | -$249.1M-54.8% | -$160.9M-89.1% | -$85.1M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
XLO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$60.6M | -$5.0M+72.8% | -$18.4M+73.2% | -$68.6M+9.4% | -$75.7M+6.2% | -$80.8M-123.7% | -$36.1M |
| Capital Expenditures | $670K | $518K+1338.9% | $36K-92.6% | $486K-74.0% | $1.9M+69.7% | $1.1M-49.7% | $2.2M |
| Free Cash Flow | -$61.3M | -$5.5M+70.1% | -$18.4M+73.4% | -$69.1M+10.9% | -$77.6M+5.2% | -$81.9M-113.8% | -$38.3M |
| Investing Cash Flow | -$670K | -$518K-1338.9% | -$36K+92.6% | -$486K+74.0% | -$1.9M-69.7% | -$1.1M+49.7% | -$2.2M |
| Financing Cash Flow | $75.8M | $87.8M+200.6% | $29.2M+545.7% | -$6.5M-9392.8% | -$69K-100.0% | $260.7M+2499.1% | $10.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
XLO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Operating Margin | -95.9% | -955.0% | N/A | N/A | N/A | N/A |
| Net Margin | -80.0% | -918.1% | N/A | N/A | N/A | N/A |
| Return on Equity | -99.3%+231.6pp | -330.9%-123.5pp | -207.5%-124.0pp | -83.5%-42.6pp | -40.9% | N/A |
| Return on Assets | -22.7%+59.3pp | -81.9%+43.5pp | -125.4%-62.0pp | -63.4%-28.6pp | -34.8%+117.3pp | -152.0% |
| Current Ratio | 2.58+0.4x | 2.21-0.8x | 3.02-2.9x | 5.89-10.0x | 15.85+14.9x | 0.93 |
| Debt-to-Equity | 3.39+0.3x | 3.04+2.4x | 0.65+0.3x | 0.32+0.1x | 0.18 | N/A |
| FCF Margin | -12.6% | -290.3% | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Xilio Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Xilio Therapeutics, Inc.'s annual revenue?
Xilio Therapeutics, Inc. (XLO) reported $43.8M in total revenue for fiscal year 2025. This represents a 589.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Xilio Therapeutics, Inc.'s revenue growing?
Xilio Therapeutics, Inc. (XLO) revenue grew by 589.9% year-over-year, from $6.3M to $43.8M in fiscal year 2025.
Is Xilio Therapeutics, Inc. profitable?
No, Xilio Therapeutics, Inc. (XLO) reported a net income of -$35.0M in fiscal year 2025, with a net profit margin of -80.0%.
What is Xilio Therapeutics, Inc.'s EBITDA?
Xilio Therapeutics, Inc. (XLO) had EBITDA of -$40.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Xilio Therapeutics, Inc.'s operating margin?
Xilio Therapeutics, Inc. (XLO) had an operating margin of -95.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Xilio Therapeutics, Inc.'s net profit margin?
Xilio Therapeutics, Inc. (XLO) had a net profit margin of -80.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Xilio Therapeutics, Inc.'s return on equity (ROE)?
Xilio Therapeutics, Inc. (XLO) has a return on equity of -99.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Xilio Therapeutics, Inc.'s free cash flow?
Xilio Therapeutics, Inc. (XLO) recorded an outflow of $5.5M in free cash flow during fiscal year 2025. This represents a 70.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Xilio Therapeutics, Inc.'s operating cash flow?
Xilio Therapeutics, Inc. (XLO) recorded an outflow of $5.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Xilio Therapeutics, Inc.'s total assets?
Xilio Therapeutics, Inc. (XLO) had $154.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Xilio Therapeutics, Inc.'s capital expenditures?
Xilio Therapeutics, Inc. (XLO) invested $518K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Xilio Therapeutics, Inc. spend on research and development?
Xilio Therapeutics, Inc. (XLO) invested $56.0M in research and development during fiscal year 2025.
What is Xilio Therapeutics, Inc.'s current ratio?
Xilio Therapeutics, Inc. (XLO) had a current ratio of 2.58 as of fiscal year 2025, which is generally considered healthy.
What is Xilio Therapeutics, Inc.'s debt-to-equity ratio?
Xilio Therapeutics, Inc. (XLO) had a debt-to-equity ratio of 3.39 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Xilio Therapeutics, Inc.'s return on assets (ROA)?
Xilio Therapeutics, Inc. (XLO) had a return on assets of -22.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Xilio Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Xilio Therapeutics, Inc. (XLO) had $137.5M in cash against an annual operating cash burn of $5.0M. This gives an estimated cash runway of approximately 331 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Xilio Therapeutics, Inc.'s Altman Z-Score?
Xilio Therapeutics, Inc. (XLO) has an Altman Z-Score of -3.41, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Xilio Therapeutics, Inc.'s Piotroski F-Score?
Xilio Therapeutics, Inc. (XLO) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Xilio Therapeutics, Inc.'s earnings high quality?
Xilio Therapeutics, Inc. (XLO) reported a net loss of $35.0M while operations used $5.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Xilio Therapeutics, Inc.?
Xilio Therapeutics, Inc. (XLO) scores 38 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.